-
1 Comment
Mediland Pharm Limited is currently in a long term downtrend where the price is trading 10.5% below its 200 day moving average.
From a valuation standpoint, the stock is 49.9% cheaper than other stocks from the Consumer Defensive sector with a price to sales ratio of 3.4.
Mediland Pharm Limited's total revenue sank by 96.3% to $727K since the same quarter in the previous year.
Its net income has dropped by 593.1% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 75.0% to $-536K since the same quarter in the previous year.
Based on the above factors, Mediland Pharm Limited gets an overall score of 2/5.
| Industry | Consumer Discretionary |
|---|---|
| Sector | Specialty Retail |
| ISIN | AU0000035362 |
| CurrencyCode | AUD |
| Exchange | AU |
| Beta | 0.54 |
|---|---|
| PE Ratio | None |
| Market Cap | 19M |
| Target Price | None |
| Dividend Yield | None |
Innlanz Limited, together with subsidiaries, engages in the retail sale of health and wellness products and supplements. The company operates through three segments: Retailer servicing the Chinese inbound tourism sector in Australia and New Zealand, Online sales through E-commerce Platform, and Hotel operations. It also operates retail stores. The company was formerly known as Mediland Pharm Limited. Innlanz Limited was founded in 2002 and is based in Parramatta, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MPH.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
